Microduplications of 16p11.2 are Associated with Schizophrenia

Abstract

Recurrent microdeletions and microduplications of a 600 kb genomic region of chromosome 16p11.2 have been implicated in childhood-onset developmental disorders. Here we report the strong association of 16p11.2 microduplications with schizophrenia in two large cohorts. In the primary sample, the microduplication was detected in 12/1906 (0.63%) cases and 1/3971 (0.03%) controls ($P=1.2\times10^{-5}$, OR=25.8). In the replication sample, the microduplication was detected in 9/2645 (0.34%) cases and 1/2420 (0.04%) controls ($P=0.022$, OR=8.3). For the series combined, microduplication of 16p11.2 was associated with 14.5-fold increased risk of schizophrenia (95% C.I. [3.3, 62]). A meta-analysis of multiple psychiatric disorders showed a significant association of the microduplication with schizophrenia, bipolar disorder and autism. The reciprocal microdeletion was associated only with autism and developmental disorders. Analysis of patient clinical data showed that head circumference was significantly larger in patients with the microdeletion compared with patients with the microduplication ($P=0.0007$). Our results suggest that the microduplication of 16p11.2 confers substantial risk for schizophrenia and other psychiatric disorders, whereas the reciprocal microdeletion is associated with contrasting clinical features.

Rare structural mutations play an important role in schizophrenia. Recent studies have shown that the genome-wide burden of rare copy number variants (CNVs) is significantly greater in patients than in healthy controls. In addition, multiple structural variants have been implicated in schizophrenia. Seminal examples include the recurrent microdeletion of 22q11.2, and a balanced translocation disrupting the gene DISC1. More recently,
recurrent microdeletions at 1q21.1, 15q13.3, 15q11.2, and copy number mutations at other genomic loci have been associated with schizophrenia in large cohorts.

We previously reported two cases of childhood-onset schizophrenia (COS) with a 600 kb microduplication of 16p11.2. This region is a well documented hot spot for recurrent rearrangements in association with autism spectrum disorders and mental retardation. Genomic hotspots such as this are important candidate loci in genetic studies of schizophrenia.

We tested the hypothesis that microduplications of 16p11.2 are associated with schizophrenia by analysis of microarray intensity data in a sample of 1906 cases and 3971 controls. Patients and controls were drawn from several different sources, as described in the supplemental note and supplementary table 1. Samples were analyzed with one of four microarray platforms (NimbleGen HD2, Affymetrix 6.0, Affymetrix 500K and ROMA 85K). Only the 16p11.2 region was examined. Thirteen microduplications and four microdeletions were detected in our primary sample using standard segmentation algorithms (Figure 1A, Supplementary Figure 1A). Microduplications were detected in 12/1906 cases (0.63%) and 1/3971 controls (0.03%), a statistically significant association (Table 1, \(P = 1.2 \times 10^{-5}, \text{OR} = 25.8 [3.3, 199] \)).

In a subset of individuals evaluated at Cold Spring Harbor Laboratory, consisting of 1352 cases and 1179 controls, CNV calls were verified by MeZOD, an independent CNV genotyping algorithm that identifies outliers in the sample based on the median probe Z-score of the target region. These results are illustrated in Figure 1 as cluster plots. All microduplications and microdeletions detected in the combined sample were experimentally validated using an independent microarray platform (Supplementary Table 2).

In order to replicate this association, we evaluated the 16p11.2 region using microarray data (Affymetrix 6.0 platform) from an independent sample of 2645 schizophrenia cases and 2420 controls. These data were collected as part of a case-control study of schizophrenia supported by the Genetic Association Information Network (GAIN, phs000021.v2.p1). We detected ten duplications and one deletion using standard HMM calling algorithms (Figure 1A). The same events were also detected using MeZOD (Figure 1E). All 16p11.2 rearrangements were validated by an independent microarray platform (Supplementary Table 2). The microduplication was detected in 9/2645 cases and 1/2420 controls, a significant association (\(P = 0.022, \text{OR} = 8.3 [1.3, 50.5] \)).

The odds ratios in our primary and replication datasets were not significantly different (Breslow-Day-Tarone test \(P = 0.46\)). Thus, our initial result was replicated in an independent sample. For the combined sample, the association of schizophrenia with microduplication at 16p11.2 was highly significant (\(P = 4.3 \times 10^{-7}, \text{OR} = 14.5 [3.3, 62] \)). Sex of the subject did not have a significant effect on the association (Supplementary Note).

Our present findings, and those from previous studies, suggest that mutations at 16p11.2 confer high risk for schizophrenia and for other neuropsychiatric disorders. Clinical variability associated with the 16p11.2 microduplication is evident from the heterogeneity of psychiatric diagnoses among microduplication carriers in five families in our series.
In these families, ten relatives carried the microduplication found in the proband. The diagnoses of these relatives were: schizophrenia (N=3), bipolar disorder (N=1), depression (N=2), psychosis signs not otherwise specified (N=1), and no mental illness (N=3). We were able to determine the parent of origin in four families, and in all cases the microduplications were inherited from a non-schizophrenic parent. The observations in these few families suggest that penetrance of the duplication is incomplete, though substantial (perhaps 30-50%), and that expression is highly variable.

In order to more precisely define the spectrum of psychiatric phenotypes associated with rearrangements of 16p11.2, we performed a meta-analysis of data on schizophrenia, bipolar disorder, and childhood developmental disorders (combining autism and global developmental delays). We integrated data from this study with four publicly available datasets \(^1,3,5,15\) to generate a combined sample of 8590 individuals with schizophrenia, 2172 with developmental delay or autism, 4822 with bipolar disorder, and 30,492 controls (Supplementary Note, Supplementary Table 3). In this combined sample, the microduplication of 16p11.2 was strongly associated with schizophrenia (Table 2, OR = 8.4 [2.8, 25.4], \(P = 4.8\times10^{-7}\)) and autism (OR = 20.7 [6.9, 61.7], \(P = 1.9\times10^{-7}\)). The association with bipolar disorder was also significant (OR = 4.3 [1.3; 14.5], \(P = 0.017\)). The reciprocal microdeletion of 16p11.2 was strongly associated with developmental delay or autism (OR = 38.7 [13.4, 111.8], \(P = 2.3\times10^{-13}\)), as reported previously\(^1,3\). However, the deletion was not associated with schizophrenia or bipolar disorder (Supplementary Note). These results suggest that the microduplication is associated with multiple psychiatric phenotypes, whereas the reciprocal microdeletion is more specifically associated with developmental delay and autism.

We explored the association of 16p11.2 microduplications and microdeletions with two clinical measures, head circumference and height. Available data were compiled from 32 patients with 16p11.2 mutations who had a diagnosis of schizophrenia, autism spectrum disorder or developmental delay (Supplementary Note, Supplementary Tables 4 and references \(^13,16\)). Z-scores for head circumference and height were calculated using standard growth charts from the Centers for Disease Control. Head circumference was greater among 23 patients with microdeletions relative to 9 patients with microduplications (Supplementary Table 5). The mean orbital frontal circumference (OFC) values of patients with microdeletions and microduplications were 1.25 and -0.28, respectively (two-tailed Wilcoxon Rank Sum Test \(P = 0.0007\)). In addition, mean head circumference of the microdeletion group was significantly greater than the population mean (\(P = 0.0001\)), whereas the mean head circumference of the microduplication group was not statistically significant (\(P = 0.29\)). The association between the 16p11.2 microdeletion and larger head circumference was observed in multiple diagnostic categories and was not specifically attributable to patients with autism (Supplemental Table 5). The microduplication and microdeletion groups did not differ significantly in height.

Microduplication of 16p11.2 is associated with increased risk of schizophrenia between 8 and 24-fold. This region joins a growing list of genomic hotspots that confer high risk for the disorder. The odds ratios in our series for the 16p11.2 microduplication and schizophrenia are comparable to odds ratios for deletions at other schizophrenia-associated
genes and regions. Deletions of 1q21.1, 15q13.3, and NRXN1 have reported odds ratios ranging from 7 to 18.5,9,10

Previous genome-wide studies of copy number variation did not find a significant association with the microduplication of 16p11.2 and schizophrenia. This event is rare, and its appearance in a cohort may be influenced by several factors, including resolution of the detection platform, methods of analysis, and chance. In the International Schizophrenia Consortium (ISC) study, microduplications spanning >50% of the 16p11.2 region were detected in 5/3391 cases and 1/3181 controls. These results are consistent with our findings, but the association did not meet the criteria for genome-wide significance in that study. In the SGENE consortium study of schizophrenia,9 the 16p11.2 microduplication was not selected as a candidate because the event was not observed in the initial phase of that study as a de novo mutation, which was the key criterion for inclusion in the association analyses.

Microduplication at 16p11.2 is associated with multiple neuropsychiatric phenotypes. Phenotypic heterogeneity has been observed for virtually all structural variants associated with schizophrenia. For example, in a large Scottish pedigree harboring a translocation disrupting DISC1, translocation carriers had diagnoses of schizophrenia, bipolar disorder, major depressive disorder, or no mental illness. Similarly, microdeletions of 1q21.17,18, 15q13.319, 22q11.220, and neurexin-121,22 are associated with adult psychiatric disorders and with autism and other pediatric neurodevelopmental disorders.

The association between the 16p11.2 microdeletion and increased head circumference is interesting given that the microdeletion appears specific to autism and developmental delay. Several studies have found increased head circumference in patients with autism, leading to the suggestion that early brain overgrowth may be a key neurobiological mechanism in the disorder. A recent study has shown that microdeletions and microduplications of 1q21.1 are associated with microcephaly and macrocephaly respectively. Taken together, these studies suggest that some mutations underlying neurodevelopmental disorders may also lead to changes in brain volume.

The 16p11.2 microduplication spans a region of approximately 600kb containing 28 genes (Supplementary Figure 1B), including multiple genes with potential roles in neurodevelopment. At least 17 of the 28 genes are expressed in the mammalian brain (Supplementary Table 6). Behavioral features have been reported in mouse knockout models of Mapk3−/−, Doc2a−/−, and Sec62−/−. Further studies are needed in order to identify the specific gene or genes in this region for which dosage effects contribute to increased risk for psychiatric and neurodevelopmental disorders.

Our findings further strengthen the evidence demonstrating a role for rare mutations in schizophrenia. Collectively, these studies demonstrate that schizophrenia is characterized by marked genetic heterogeneity. The 16p11.2 locus by itself accounts for only a small fraction of the illness. At the same time, duplication of this region confers substantial risk to the individuals who carry it. The fact that a single mutation is rare does not negate its potential relevance to the broader patient population. The collective effect of rare mutations at many different loci may account for a substantial proportion of affected
individuals\textsuperscript{4,5}. Furthermore, the microduplication of 16p11.2 and rare mutations at other loci will likely impact overlapping neurobiological pathways. Characterizing these critical brain processes will contribute substantially to our understanding of the origins of schizophrenia and provide important targets for treatment development.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Authors**

Shane McCarthy\textsuperscript{1}, Vladimir Makarov\textsuperscript{1}, George Kirov\textsuperscript{2}, Anjene Addington\textsuperscript{3}, Jon McClellan\textsuperscript{4}, Seungho Yoon\textsuperscript{1}, Dianna Perkins\textsuperscript{5}, Diane E. Dickel\textsuperscript{6}, Mary Kusenda\textsuperscript{1,7}, Olga Krastoshevska\textsuperscript{8}, Verena Krause\textsuperscript{8}, Ravinesh A. Kumar\textsuperscript{9}, Detelina Grozeva\textsuperscript{2}, Dheeraj Malhotra\textsuperscript{1}, Tom Walsh\textsuperscript{6}, Elaine H. Zackai\textsuperscript{10}, Paige Kaplan\textsuperscript{11}, Jaya Ganesh\textsuperscript{11}, Ian D. Krantz\textsuperscript{10}, Nancy B. Spinner\textsuperscript{10}, Patricia Roccaanova\textsuperscript{1}, Abhishek Bhandari\textsuperscript{1}, Kevin Pavon\textsuperscript{1}, B. Lakshmi\textsuperscript{1,12}, Anthony Leotta\textsuperscript{1}, Jude Kendall\textsuperscript{1}, Yoon-ha Lee\textsuperscript{1}, Vladimir Vacic\textsuperscript{1}, Sydnei Gary\textsuperscript{1}, Lilia Iakoucheva\textsuperscript{13}, Timothy J. Crow\textsuperscript{14}, Susan L. Christian\textsuperscript{9}, Jeffrey Lieberman\textsuperscript{15}, Scott Stroup\textsuperscript{5}, Terho Lehtimäki\textsuperscript{16}, Kaija Puura\textsuperscript{17}, Chad Haldeman-Englert\textsuperscript{10}, Justin Pearl\textsuperscript{18}, Meredith Goodell\textsuperscript{19}, Virginia L. Willour\textsuperscript{19}, Pamela DeRosse\textsuperscript{20}, Jo Steele\textsuperscript{18}, Layla Kassem\textsuperscript{18}, Jessica Wolff\textsuperscript{18}, Nisha Chitkara\textsuperscript{20}, Francis J. McMahon\textsuperscript{18}, Anil K. Malhotra\textsuperscript{20}, James B. Potash\textsuperscript{19}, Thomas G. Schulze\textsuperscript{18,21}, Markus M. Nöthen\textsuperscript{22,23}, Sven Cichon\textsuperscript{22,23}, Marcella Rietschel\textsuperscript{21,24}, Ellen Leibenluft\textsuperscript{25}, Vlad Kustanovich\textsuperscript{26}, Clara M. Lajonchere\textsuperscript{26}, James S. Sutcliffe\textsuperscript{27}, David Skuse\textsuperscript{28}, Michael Gill\textsuperscript{29}, Louise Gallagher\textsuperscript{29}, Nancy R. Mendell\textsuperscript{30}, Wellcome Trust Case Control Consortium\textsuperscript{31}, Nick Craddock\textsuperscript{2}, Michael J. Owen\textsuperscript{2}, Michael C. O’Donovan\textsuperscript{2}, Tamim H. Shaikh\textsuperscript{10}, Ezra Susser\textsuperscript{15}, Lynn E. DeLisi\textsuperscript{32,33}, Patrick F. Sullivan\textsuperscript{34}, Curtis K. Deutsch\textsuperscript{32,35}, Judith Rapoport\textsuperscript{3}, Deborah L. Levy\textsuperscript{8,32}, Mary-Claire King\textsuperscript{6}, and Jonathan Sebat\textsuperscript{1}

**Affiliations**

\textsuperscript{1}Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA \textsuperscript{2}Department of Psychological Medicine, School of Medicine, Cardiff University, Cardiff, UK \textsuperscript{3}Child Psychiatry Branch, National Institute for Mental Health, National Institutes of Health, Bethesda, Maryland, USA \textsuperscript{4}Department of Psychiatry, University of Washington, Seattle, Washington, USA \textsuperscript{5}Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina USA \textsuperscript{6}Department of Genome Sciences, University of Washington, Seattle, Washington, USA \textsuperscript{7}Graduate Program in Genetics State University of New York, Stony Brook, New York, USA \textsuperscript{8}Psychology Research Laboratory, McLean Hospital, Belmont, Massachusetts, USA \textsuperscript{9}Department of Human Genetics, University of Chicago, Chicago, Illinois, USA \textsuperscript{10}Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA \textsuperscript{11}Section of Biochemical Genetics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA \textsuperscript{12}Ontario Institute for Cancer Research, Toronto, Ontario, Canada \textsuperscript{13}Laboratory of Statistical Genetics, The Rockefeller University, New York, USA \textsuperscript{14}The Prince of Wales International Center for SANE Research,

*Nat Genet.* Author manuscript; available in PMC 2010 October 07.
Acknowledgments

Funding for this study was provided by grants from Ted and Vada Stanley, the Simons Foundation, grants from NARSAD to FJM, TGS, DLL, MCK and TW, and grants from the Essel Foundation and the Sidney R. Baer, Jr. Foundation to DLL and from the Margaret Price Investigatorship to JBP and VLW. This work was supported by grants from the National Institutes of Health Intramural Research Program, National Institutes of Health, including NIMH grant MH076431 to JS, which reflects co-funding from Autism Speaks, and the Southwestern Autism Research and Resource Center, as well as NIH grants to JS (HF004222), MCK, TW, and JMC (MH083989), DLL and NRM (MH071523; MH31340), JMC (RR00037, PFS (MH074027 and MH077139), JSS (MH061009), LED (MH44245), TSH (GM081519) and CKD (MH081810; DE016442; HD04147). Funding for GK, NC, MJO and MCO was provided by the Medical Research Council, UK, and the Wellcome Trust. The CATIE project was funded by NIMH contract N01 MH90001. Genotyping of the Molecular Genetics of Schizophrenia study (PI Pablo Gejman) was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health. Genotype data were obtained from dbGaP (http://www.ncbi.nlm.nih.gov/dbgap, accession number phs000021.v2.p1). This study makes use of data generated by the Wellcome Trust Case Control Consortium (full list of contributors is presented in the supplementary online material). Funding for that project was provided by the Wellcome Trust under award 076113. Microarray data and clinical information were provided by the Genetic Association Information Network (GAIN). Thanks to the New York Cancer Project, Peter Gregersen and Annette Lee for providing population control samples. Also, we wish to thank Drs. Pablo Gejman and Douglas Levinson for helpful discussions. Special thanks to Dr. James Watson for helpful discussions and support.

References

1. Weiss LA, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008; 358:667–75. [PubMed: 18184952]
2. Kumar RA, et al. Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet. 2008; 17:628–38. [PubMed: 18156158]
3. Marshall CR, et al. Structural Variation of Chromosomes in Autism Spectrum Disorder. The American Journal of Human Genetics. 2008; 82:477–488. [PubMed: 18252227]
4. Walsh T, et al. Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia. Science. 2008; 320:539–543. [PubMed: 18369103]
5. Stone JL, et al. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008; 455:237–241. [PubMed: 18668038]
6. Kirov G, et al. Support for the involvement of large cnvs in the pathogenesis of schizophrenia. Hum Mol Genet. 2009; 14:796–803.
7. Karayiorgou M, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A. 1995; 92:7612–6. [PubMed: 7644464]
8. Millar JK, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000; 9:1415–23. [PubMed: 10814723]
9. Stefansson H, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008
10. Rujescu D, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet. 2008
11. Friedman JI, et al. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry. 2008; 13:261–6. [PubMed: 17646849]
12. Kirov G, et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 2008; 17:458–65. [PubMed: 17989066]
13. Ghebranious N, Giampietro PF, Wesbrook FP, Rezkalha SH. A novel microdeletion at 16p11.2 harbors candidate genes for aortic valve development, seizure disorder, and mild mental retardation. Am J Med Genet A. 2007; 143:1462–71. [PubMed: 17568417]
14. Sebat J, et al. Strong association of de novo copy number variations with autism. Science. 2007; 316:445–9. [PubMed: 17363630]
15. Manolio TA, et al. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet. 2007; 39:1045–51. [PubMed: 17728769]
16. Bijlsma EK, et al. Extending the phenotype of recurrent rearrangements of 16p11.2: deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet. 2009
17. Jefford HC, et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med. 2008; 359:1685–99. [PubMed: 18784092]
18. Brunetti-Pierri N, et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet. 2008; 40:1466–71. [PubMed: 19029900]
19. Sharp AJ, et al. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet. 2006; 38:1038–42. [PubMed: 16906162]
20. Ousley O, Rockers K, Dell ML, Coleman K, Cubells JF. A review of neurocognitive and behavioral profile associated with 22q11 deletion syndrome: implications for clinical evaluation and treatment. Curr Psychiatry Rep. 2007; 9:148–58. [PubMed: 17389127]
21. Kim HG, et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet. 2008; 82:199–207. [PubMed: 18179900]
22. Szatmari P, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet. 2007; 39:319–28. [PubMed: 17322880]
23. Woodhouse W, et al. Head circumference in autism and other pervasive developmental disorders. J Child Psychol Psychiatry. 1996; 37:665–71. [PubMed: 8894947]
24. Fidler DJ, Bailey JN, Smalley SL. Macrocephaly in autism and other pervasive developmental disorders. Dev Med Child Neurol. 2000; 42:737–40. [PubMed: 11104344]
25. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. Jama. 2003; 290:337–44. [PubMed: 12865374]
26. Butler MG, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet. 2005; 42:318–21. [PubMed: 15805158]
27. Dementieva YA, et al. Accelerated head growth in early development of individuals with autism. Pediatr Neurol. 2005; 32:102–8. [PubMed: 15664769]
28. Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry. 2005; 58:1–9. [PubMed: 15935993]
29. Lainhart JE, et al. Head circumference and height in autism: a study by the Collaborative Program of Excellence in Autism. Am J Med Genet A. 2006; 140:2257–74. [PubMed: 17022081]
30. Fukumoto A, et al. Growth of head circumference in autistic infants during the first year of life. J Autism Dev Disord. 2008; 38:411–8. [PubMed: 17647099]
31. Courchesne E, et al. Mapping early brain development in autism. Neuron. 2007; 56:399–413. [PubMed: 17964254]
32. Mazzucchelli C, et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron. 2002; 34:807–20. [PubMed: 12062026]
33. Sakaguchi G, et al. Doc2alpha is an activity-dependent modulator of excitatory synaptic transmission. Eur J Neurosci. 1999; 11:4262–8. [PubMed: 10594652]
34. Miyazaki T, et al. Disturbance of cerebellar synaptic maturation in mutant mice lacking BSRPs, a novel brain-specific receptor-like protein family. FEBS Lett. 2006; 580:4057–64. [PubMed: 16814779]
35. Sebat J, et al. Large-scale copy number polymorphism in the human genome. Science. 2004; 305:525–8. [PubMed: 15273396]
36. Diskin SJ, et al. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res. 2008; 36:e126. [PubMed: 18784189]
37. Grubor V, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood. 2009; 113:1294–303. [PubMed: 18922857]
38. McCarroll SA, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008; 40:1166–74. [PubMed: 18776908]
39. Cooper GM, Zerr T, Kidd JM, Eichler EE, Nickerson DA. Systematic assessment of copy number variant detection via genome-wide SNP genotyping. Nat Genet. 2008; 40:1199–203. [PubMed: 18776910]
40. Deutsch, CK. Head Circumference in autism. In: Neisworth, J.; Wolfe, P., editors. Autism and PDD Dictionary. Brookes; Baltimore MD: 2004.
41. Deutsch, CK.; Farkas, LG. Quantitative methods of dysmorphology diagnosis. In: Farkas, LG., editor. Anthropometry of the head and face. Raven; New York: 1994. p. 151-158.

Nat Genet. Author manuscript; available in PMC 2010 October 07.
Figure 1. Microduplications and microdeletions at 16p11.2 in persons with schizophrenia and controls

(A) 16p11.2 rearrangements were detected in a primary sample of 1906 cases and 3971 controls (Panels A, B, C, D) and a replication sample of 2645 cases and 2420 controls (Panel A, E). The single microduplication and three microdeletions detected in the primary control set are presented based on the Affymetrix 500K coordinates (hg18). All other CNVs were validated in the NimbleGen HD2 platform and are illustrated based on the validation coordinates (Panels B, C, D, E). The median z-score for the 535kb 16p11.2 target region is plotted on the X-axis and the median z-score of flanking invariant probes is plotted on the Y-axis. Data are presented separately for the ROMA (B), Affymetrix500K (C), NimbleGen HD2 (D), and (Affymetrix 6.0 (E) platforms. CNVs were called using thresholds of >2 SD for ROMA and >1 SD for all other platforms (●). MeZOD and the HMM algorithms detected the same deletions and duplications at 16p11.2.
Table 1

Duplications and deletions at 16p11.2 among persons with schizophrenia and controls

| Series  | Diagnosis | Subjects | Deletions | Duplications | OR [95% C.I.] | P-Value |
|---------|-----------|----------|-----------|--------------|---------------|---------|
|         |           | N        | N         | %            | N             | %       |         |
|         | Primary   |          |           |              |               |         |         |
|         | Schizophrenia | 1906     | 1         | 0.05         | 12            | 0.63    | 25.8 [3.3, 199] | 1.2×10⁻⁵ |
|         | Controls   | 3971     | 3         | 0.08         | 1             | 0.03    |         |         |
|         | Replication |         |           |              |               |         |         |
|         | Schizophrenia | 2645     | 0         | 0.00         | 9             | 0.34    | 8.3 [1.3, 50.5] | 0.022 |
|         | Controls   | 2420     | 1         | 0.04         | 1             | 0.04    |         |         |
|         | Combined   |         |           |              |               |         |         |
|         | Schizophrenia | 5877     | 1         | 0.02         | 21            | 0.36    | 14.5 [3.3, 62.0] | 4.3×10⁻⁵ |
|         | Controls   | 6391     | 4         | 0.06         | 2             | 0.03    |         |         |

In the primary sample, which consisted of patients and controls genotyped using one of 3 microarray platforms, association was calculated using the Cochran-Mantel-Haenszel exact test using array type as a stratifying variable. Combined odds ratio estimates and 95% confidence intervals were calculated using a logistic regression with disease group and array-type as factors. In the replication sample, which consisted of patients and controls assessed on a single microarray platform, association was calculated using a Fisher’s exact test. Deletions did not show a significant association with schizophrenia or in controls.
## Table 2

Meta-analysis of 16p11.2 rearrangements in schizophrenia, autism and developmental delay, and bipolar disorder

| Diagnosis                  | Subjects | Deletions | Duplications | Deletions | Duplications |
|---------------------------|----------|-----------|--------------|-----------|--------------|
|                           | N        | N %       | OR[95% C.I.] | P-Value   | N %          | OR[95% C.I.] | P-Value |
| Schizophrenia             | 8590     | 3 0.03    | NC*          |           | 26 0.30      | 8.4 [2.8, 25.4] | 4.8×10⁻⁷ |
| Controls                  | 28406    | 9 0.03    |              |           | 8 0.03       |              |         |
| Autism or Developmental Delay | 2172 | 17 0.78   | 38.7 [13.4,111.8] | 2.3×10⁻¹³ | 10 0.46      | 20.7 [6.9,61.7] | 1.9×10⁻⁷ |
| Controls                  | 24891    | 5 0.02    |              |           | 6 0.02       |              |         |
| Bipolar Disorder          | 4822     | 4 0.08    |              |           | 6 0.12       | 4.3 [1.3; 14.5] | 0.017  |
| Controls                  | 25225    | 6 0.02    |              |           | 7 0.03       |              |         |

*Not calculated (NC) because significant heterogeneity among studies was detected by the Breslow-Day Tarone test. The partial odds ratios [95%CI] for the deletion in schizophrenia were 0.69 [0.1, 4.9], 0.3 [0.05, 2.2], 14.6 [1.9, 111.2], and 0.3 [0.03, 3.7] and partial odds ratios for the deletion in bipolar disorder were 0.3[0.03,3.3], 0.55[0.05,6.7], 25[5.4,117] in this study, the GAIN study and the Weiss et al. studies, respectively.

Data from four studies reporting microduplications and microdeletions of 16p11.2 in schizophrenia, autism and/or bipolar disorder were combined with data from the Primary Sample to assess the relative strength of the association of each variant with each disorder. Associations were calculated using the Cochran-Mantel-Haenszel exact test, using source as a stratifying variable. Combined odds ratio estimates and confidence intervals were calculated from logistic regression with disease group and source (study) as factors.